S
0.421
0.02 (3.85%)
| Previous Close | 0.406 |
| Open | 0.426 |
| Volume | 130,739 |
| Avg. Volume (3M) | 141,700 |
| Market Cap | 2,635,739 |
| Price / Book | 3.60 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -3.30 |
| Total Debt/Equity (MRQ) | 165.48% |
| Current Ratio (MRQ) | 1.44 |
| Operating Cash Flow (TTM) | -7.33 M |
| Levered Free Cash Flow (TTM) | -4.18 M |
| Return on Assets (TTM) | -113.74% |
| Return on Equity (TTM) | -383.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Shuttle Pharmaceuticals Holding | - | - |
AIStockmoo Score
-0.5
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.50 |
|
Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 27.06% |
| % Held by Institutions | 6.14% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Mar 2025 | Announcement | Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering |
| 12 Mar 2025 | Announcement | Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities |
| 12 Mar 2025 | Announcement | Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering |
| 26 Feb 2025 | Announcement | Shuttle Pharma Provides Corporate Update and Reports 2024 Results |
| 21 Jan 2025 | Announcement | Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma |
| 07 Jan 2025 | Announcement | Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |